This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-4447v1 69/17/6773    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Brady, S. C. Articles by Olson, M. F. PubMed PubMed Citation Articles by Brady, S. C. Articles by Olson, M. F.

Sprouty2 Association with B-Raf Is Regulated by Phosphorylation and Kinase Conformation

¹ The Beatson Institute for Cancer Research, Glasgow, United Kingdom; ² Henry Wellcome Building for Molecular Physiology and ³ Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom; and ⁴ MRC Protein Phosphorylation Unit, University of Dundee, Dundee, United Kingdom

Requests for reprints: Michael F. Olson, The Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow G61 1BD, United Kingdom. Phone: 44-41-330-3654; Fax: 44-41-942-6521; E-mail: m.olson{at}beatson.gla.ac.uk.

Key Words: Sprouty • B-Raf • MAPK • signal transduction • ERK

Sprouty2 is a feedback regulator that controls the Ras/Raf/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase (MAPK) pathway at multiple levels, one way being through direct interaction with Raf kinases. Consistent with a role as a tumor suppressor, Sprouty2 expression is often down-regulated in human cancers. However, Sprouty2 is up-regulated in some cancers, suggesting the existence of posttranscriptional mechanisms that permit evasion of Sprouty2-mediated antitumorigenic properties. We report that MAPK activation induces Sprouty2 phosphorylation on six serine residues, which reduced Sprouty2 association with wild-type B-Raf. Mutation of these six serines to nonphosphorylatable alanines increased the ability of Sprouty2 to inhibit growth factor–induced MAPK activation. Oncogenic B-Raf mutants such as B-Raf V600E did not associate with Sprouty2, but this resistance to Sprouty2 binding was not due to phosphorylation. Instead, the active kinase conformation induced by oncogenic mutation prevents Sprouty2 binding. These results reveal a dual mechanism that affects the Sprouty2/B-Raf interaction: Sprouty phosphorylation and B-Raf conformation. [Cancer Res 2009;69(17):6773–81]

This article has been cited by other articles:

				G. Schaaf, M. Hamdi, D. Zwijnenburg, A. Lakeman, D. Geerts, R. Versteeg, and M. Kool Silencing of SPRY1 Triggers Complete Regression of Rhabdomyosarcoma Tumors Carrying a Mutated RAS Gene Cancer Res., January 15, 2010; 70(2): 762 - 771. [Abstract] [Full Text] [PDF]

				F. Edwin, K. Anderson, and T. B. Patel HECT Domain-containing E3 Ubiquitin Ligase Nedd4 Interacts with and Ubiquitinates Sprouty2 J. Biol. Chem., January 1, 2010; 285(1): 255 - 264. [Abstract] [Full Text] [PDF]